Guselkumab is recommended for those who have previously been exposed to two conventional DMARDs and one biologic, unless contraindicated.

Guselkumab improves axial symptoms relative to placebo in people with axial psoriatic arthritis and radiographic evidence of sacroiliitis, shows a post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies.

Guselkumab (TREMFYA®) treats psoriatic arthritis via a novel mechanism of action.

Laura Coates outlines the findings from a phase 3b trial of guselkumab versus placebo in patients with psoriatic arthritis and an inadequate response to TNF inhibitors.

Findings from the phase 3b COSMOS trial indicate that guselkumab, a selective monoclonal antibody targeting the IL-23 p19 subunit, may improve outcomes for patients with active psoriatic arthritis and an inadequate response to TNF inhibitors.

medwireNews : The European Commission has approved guselkumab, a monoclonal antibody targeting interleukin (IL)-23, for the treatment of psoriatic arthritis (PsA).

medwireNews : The interleukin (IL)-23 inhibitor guselkumab has been approved for the treatment of psoriatic arthritis (PsA) in the USA.

Findings from the DISCOVER-1 and DISCOVER-2 trials suggest that the interleukin-23 inhibitor guselkumab may be a promising treatment option for people with psoriatic arthritis.

The 1-year results from the DISCOVER-1 and DISCOVER-2 trials point to prolonged benefits of the interleukin-23 inhibitor guselkumab in patients with psoriatic arthritis.

Patients with active psoriatic arthritis continue to derive clinical benefit from the interleukin-23 inhibitor guselkumab over around a year of treatment, indicate follow-up results from a phase IIa trial.

Sunday,   November 10, 11:45–12:00. Georgia World Congress Center, Atlanta, USA Presenting author:  Atul Deodhar, USA TRIAL RESULTS PUBLISHED  | R ead the full story What our Advisory Board said: This will provide the first phase III data in psoriatic arthritis (PsA) for a p19/anti-IL23 antibody. These are being used increasingly frequently in dermatology practice for psoriasis. It is important to assess the efficacy on musculoskeletal symptoms as well as skin disease, in order to help choose biologics optimally for our patients with psoriasis and PsA. – Laura Coates, UK

Findings from a systematic review and network meta-analysis suggest that different biologics have similar efficacy for the joint manifestations of psoriatic arthritis, but IL-17A-targeted therapies or guselkumab may be the best choice for skin responses.

Oliver FitzGerald comments on the findings from the DISCOVER-1 and DISCOVER-2 trials, which demonstrated the efficacy of guselkumab for the treatment of psoriatic arthritis (3:36).

Lead investigator Philip Mease outlines the results of the DISCOVER-2 trial, and discusses how guselkumab may impact the psoriatic arthritis treatment landscape (8:26).

Participants were randomly assigned to receive 48 weeks of treatment with either guselkumab 100 mg every 4 weeks, 100 mg every 8 weeks (after loading doses at weeks 0 and 4), or placebo for 24 weeks followed by guselkumab 100 mg every 4 weeks for the remaining 24 weeks.

News story | Guselkumab shows promise for PsA Researcher comment | The DISCOVER-2 trial Expert commentary | The DISCOVER trials

This phase III trial investigates the efficacy and safety of guselkumab in patients with psoriatic arthritis. Sunday, November 10, 11:00–12:30

She adds that the IL-23 specific inhibitors guselkumab and tildrakizumab, which are currently approved for the treatment of psoriasis, along with the IL-23 inhibitors risankizumab and mirikizumab that are presently under investigation, “work very well for skin and their effect on the joints is currently being evaluated.”

“We've seen good results in both the skin disease as well as the musculoskeletal manifestations” of PsA with both risankizumab and another IL-23 inhibitor, guselkumab, Mease told medwireNews .

Guselkumab was “well tolerated with no unexpected safety findings,” said Deodhar.